Department of Systems and Computational Biology, Albert Einstein College of Medicine, 1300 Morris Park Ave., The Bronx, NY 10461, USA.
Department of Systems and Computational Biology, Albert Einstein College of Medicine, 1300 Morris Park Ave., The Bronx, NY 10461, USA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Ave., The Bronx, NY 10461, USA.
Cell Metab. 2019 Aug 6;30(2):235-237. doi: 10.1016/j.cmet.2019.07.005.
Levodopa (L-dopa) is the primary treatment for Parkinson's disease. The gut microbiome can metabolize levodopa, potentially leading to decreased efficacy and side effects, but responsible bacteria were unknown. Maini Rekdal et al. (2019) characterize enzymes in two gut bacteria that sequentially metabolize L-dopa and identify a novel inhibitor that may improve outcomes.
左旋多巴(L-dopa)是治疗帕金森病的主要药物。肠道微生物组可以代谢左旋多巴,从而可能导致疗效降低和副作用,但具体的相关细菌尚不清楚。Maini Rekdal 等人(2019 年)描述了两种肠道细菌中先后代谢 L-dopa 的酶,并鉴定出一种可能改善治疗效果的新型抑制剂。